#United States #Class Action #Los Angeles #Schall Law Firm #Ssoleno Therapeutics

Recent Securities Fraud Lawsuit Against Soleno Therapeutics

The Schall Law Firm, a prominent legal entity specialized in protecting shareholder rights, has recently issued an alert for investors concerning a class action lawsuit targeting Soleno Therapeutics, Inc. This litigation stems from allegations concerning securities fraud that potentially jeopardized investors' interests during a specific period of trading in the company's stock.

Overview of the Lawsuit

The class action case is rooted in claims that Soleno Therapeutics violated the Securities Exchange Act of 1934, specifically sections 10(b) and 20(a), as well as Rule 10b-5. These legal provisions are designed to uphold the integrity of financial markets by prohibiting fraud, misrepresentations, or omissions of material facts by companies regarding their securities.

Investors who purchased shares of Soleno between March 26, 2025, and November 4, 2025, are particularly encouraged to make contact with The Schall Law Firm prior to the forthcoming deadline of May 5, 2026. Many shareholders may not be aware that they have rights and options for seeking compensation for potential losses incurred during this timeframe.

Legal Implications and Next Steps

Potential participants are advised to reach out to Brian Schall from the firm to explore their rights, free of charge. While the class has not yet received official certification as per legal procedures, early engagement in the lawsuit process fosters a higher likelihood of a successful outcome. Investors need to understand that failing to take action may render them as absent class members, thus forfeiting the chance to recover any losses incurred.

Misleading Statements and Investor Impact

At the heart of the lawsuit lies a serious contention: Soleno Therapeutics allegedly issued false and misleading statements regarding its flagship treatment, diazoxide choline extended-release tablets (DCCR), which were under scrutiny due to safety concerns. Notably, this litigation contends that the company downplayed significant evidence about safety risks linked with DCCR, highlighting that the treatment was fraught with more safety issues than previously acknowledged.

The complaint further alleges that the DCCR's commercial viability was overly optimistic and that adverse event risks were materially higher than disclosed. Investors relied on the company's public statements, believing them to represent the true risk profile of the treatment and the company's standing. When the truth came to light regarding the safety risks associated with the treatment, it adversely affected Soleno Therapeutics' stock price, leading to financial harm for investors.

The Firm’s Commitment to Investors

The Schall Law Firm has positioned itself as an advocate for shareholders around the globe, with a solid history of handling securities class action lawsuits and other forms of litigation aimed at protecting investors. This particular case against Soleno is a vital opportunity for stakeholders to hold the company accountable and recover losses that stem from alleged fraud. Participation could provide a pathway for affected shareholders to assert their rights under securities law and potentially reclaim their investments.

If you are a concerned investor, do not hesitate. Engage with The Schall Law Firm to understand your legal standing and the steps you can take towards recovering your financial losses.

To contact the firm, reach out via their official website or contact Brian Schall at their Los Angeles office directly. Act now to ensure your voice is heard in this class action lawsuit and take a stand against financial misconduct.